Tag : B/F/TAF

Approximately 3.1 million people worldwide live with concomitant human immunodeficiency virus-1 (HIV-1) and hepatitis B virus (HBV) infection. Current guidelines recommend tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)-based antiretroviral therapies for most adults